TELA Bio director awarded 23,600 RSUs, 34,885 options

TELA Bio, Inc. director Guy P. Nohra reported compensation-related equity awards in the form of common stock and stock options.

Rhea-AI Filing Summary

TELA Bio, Inc. director Guy P. Nohra reported compensation-related equity awards in the form of common stock and stock options. On June 9, 2026, he received 11,675 restricted stock units that vest in three equal annual installments beginning on June 9, 2027, and an additional 11,925 restricted stock units that vest on the earlier of June 9, 2027, the next annual meeting of stockholders, or a Change in Control, subject to continued service.

Following these awards, Nohra directly holds 23,600 shares of common stock from one grant and 11,925 shares from the other. He was also granted stock options for 17,335 and 17,550 shares of common stock at an exercise price of $0.935 per share, expiring on June 9, 2036. One option vests in 36 equal monthly installments starting June 9, 2026, and the other vests on the earlier of June 9, 2027, the next annual meeting, or a Change in Control, in each case conditioned on his continued service.

Insider Trade Summary

Grant/Award: 58,485 shares

Grant/Award 4 txns

Insider NOHRA GUY P

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	17,550	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	17,335	$0.00	$0.00
Grant/Award	Common Stock	11,925	$0.00	$0.00
Grant/Award	Common Stock	11,675	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 34,885 contracts (Direct); Common Stock — 23,600 shares (Direct)

Footnotes (4)

1. F1. These restricted stock units will vest in three equal annual installments beginning on June 9, 2027, in each case subject to the Reporting Person's continued service through the applicable vesting date.
2. F2. These restricted stock units vest on the earlier of (a) June 9, 2027, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date.
3. F3. The option vests in 36 equal monthly installments on each monthly anniversary of June 9, 2026, in each case subject to the Reporting Person's continued service through the applicable vesting date.
4. F4. The option vests on the earlier of (a) June 9, 2027, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 06:04 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

NOHRA GUY P

(Last) (First) (Middle)

C/O TELA BIO, INC.

1 GREAT VALLEY PARKWAY, SUITE 24

(Street)

MALVERN PENNSYLVANIA 19355

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TELA Bio, Inc. [ TELA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/09/2026		A		11,925(1)	A	$0	11,925	D
Common Stock	06/09/2026		A		11,675(2)	A	$0	23,600	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.935	06/09/2026		A		17,550		(3)	06/09/2036	Common Stock	17,550	$0	17,550	D
Stock Option (Right to Buy)	$0.935	06/09/2026		A		17,335		(4)	06/09/2036	Common Stock	17,335	$0	17,335	D

Explanation of Responses:

1. These restricted stock units will vest in three equal annual installments beginning on June 9, 2027, in each case subject to the Reporting Person's continued service through the applicable vesting date.

2. These restricted stock units vest on the earlier of (a) June 9, 2027, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date.

3. The option vests in 36 equal monthly installments on each monthly anniversary of June 9, 2026, in each case subject to the Reporting Person's continued service through the applicable vesting date.

4. The option vests on the earlier of (a) June 9, 2027, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ Megan Smeykal, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)